Demonstration of extracellular peptidylarginine deiminase (PAD) activity in synovial fluid of patients with rheumatoid arthritis using a novel assay for citrullination of fibrinogen

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Damgaard, Dres ^a   Senolt, Ladislav ^b   Nielsen, Friberg ^a   Pruijn, Ger J ^c   Nielsen, Claus H ^a  

^a Rigshospitalet   (Denmark)

^b CHARLES UNIVERSITY   (Czech Republic)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CITRULLINATED FIBRINOGEN ANTIBODY; FIBRINOGEN; PROTEIN ANTIBODY; PROTEIN ARGININE DEIMINASE; PROTEIN ARGININE DEIMINASE 2; PROTEIN ARGININE DEIMINASE 4; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG; CITRULLINE; HYDROLASE; PROTEIN-ARGININE DEIMINASE;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SPECIFICITY; FEMALE; HUMAN; IMMUNOASSAY; IN VITRO STUDY; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; SYNOVIAL FLUID LEVEL; ARTHRITIS, RHEUMATOID; ENZYME ACTIVATION; ENZYMOLOGY; EXTRACELLULAR SPACE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROCEDURES;

AGED; ARTHRITIS, RHEUMATOID; CITRULLINE; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SPACE; FEMALE; FIBRINOGEN; HUMANS; HYDROLASES; MALE; MIDDLE AGED; SYNOVIAL FLUID;

EID: 84924325825     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-014-0498-9     Document Type: Article

References (38)

1. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ: PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003, 25:1106-1118.
2. Senshu T, Kan S, Ogawa H, Manabe M, Asaga H: Preferential deimination of keratin K1 and filaggrin during the terminal differentiation of human epidermis. Biochem Biophys Res Commun 1996, 225:712-719.
3. Harauz G, Musse AA: A tale of two citrullines-structural and functional aspects of myelin basic protein deimination in health and disease. Neurochem Res 2007, 32:137-158.
4. Mortier A, Gouwy M, Van Damme J, Proost P: Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. Exp Cell Res 2011, 317:642-654.
5. Li P, Li M, Lindberg MR, Kennett MJ, Xiong N, Wang Y: PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med 2010, 207:1853-1862.
6. György B, Tóth E, Tarcsa E, Falus A, Buzás EI: Citrullination: a posttranslational modification in health and disease. Int J Biochem Cell Biol 2006, 38:1662-1677.
7. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ: Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998, 101:273-281.
8. Feitsma AL, van der Voort EI, Franken KL, el Bannoudi H, Elferink BG, Drijfhout JW, Huizinga TW, de Vries RR, Toes RE, Ioan-Facsinay A: Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. Arthritis Rheum 2010, 62:117-125.
9. Gregersen PK, Silver J, Winchester RJ: The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987, 30:1205-1213.
10. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E: Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003, 171:538-541.
11. Nakayama-Hamada M, Suzuki A, Kubota K, Takazawa T, Ohsaka M, Kawaida R, Ono M, Kasuya A, Furukawa H, Yamada R, Yamamoto K: Comparison of enzymatic properties between hPADI2 and hPADI4. Biochem Biophys Res Commun 2005, 327:192-200.
12. Moscarello MA, Mastronardi FG, Wood DD: The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem Res 2007, 32:251-256.
13. Ishigami A, Ohsawa T, Hiratsuka M, Taguchi H, Kobayashi S, Saito Y, Murayama S, Asaga H, Toda T, Kimura N, Maruyama N: Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer's disease. J Neurosci Res 2005, 80:120-128.
14. Zendman AJ, Raijmakers R, Nijenhuis S, Vossenaar ER, Tillaart M, Chirivi RG, Raats JM, van Venrooij WJ, Drijfhout JW, Pruijn GJ: ABAP: antibody-based assay for peptidylarginine deiminase activity. Anal Biochem 2007, 369:232-240.
15. Foulquier C, Sebbag M, Clavel C, Chapuy-Regaud S, Al Badine R, Méchin MC, Vincent C, Nachat R, Yamada M, Takahara H, Simon M, Guerrin M, Serre G: Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 2007, 56:3541-3553.
16. van Beers JJ, Schwarte CM, Stammen-Vogelzangs J, Oosterink E, Božič B, Pruijn GJ: The rheumatoid arthritis synovial fluid citrullinome reveals novel citrullinated epitopes in apolipoprotein E, myeloid nuclear differentiation antigen, and β-actin. Arthritis Rheum 2013, 65:69-80.
17. 2+ -induced activation of human PAD4. Nat Struct Mol Biol 2004, 11:777-783.
18. Takahara H, Okamoto H, Sugawara K: Calcium-dependent properties of peptidylarginine deiminase from rabbit skeletal muscle. Agric Biol Chem 1986, 50:2899-2904.
19. Darrah E, Giles JT, Ols ML, Bull HG, Andrade F, Rosen A: Erosive rheumatoid arthritis is associated with antibodies that activate PAD4 by increasing calcium sensitivity. Sci Transl Med 2013, 5:186ra65.
20. Arandjelovic S, McKenney KR, Leming SS, Mowen KA: ATP induces protein arginine deiminase 2-dependent citrullination in mast cells through the P2X7 purinergic receptor. J Immunol 2012, 189:4112-4122.
21. Van Steendam K, Tilleman K, De Ceuleneer M, De Keyser F, Elewaut D, Deforce D: Citrullinated vimentin as an important antigen in immune complexes from synovial fluid of rheumatoid arthritis patients with antibodies against citrullinated proteins. Arthritis Res Ther 2010, 12:R132.
22. Zhao X, Okeke NL, Sharpe O, Batliwalla FM, Lee AT, Ho PP, Tomooka BH, Gregersen PK, Robinson WH: Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther 2008, 10:R94.
23. Fan LY, He DY, Wang Q, Zong M, Zhang H, Yang L, Sun LS: Citrullinated vimentin stimulates proliferation, pro-inflammatory cytokine secretion, and PADI4 and RANKL expression of fibroblast-like synoviocytes in rheumatoid arthritis. Scand J Rheumatol 2012, 41:354-358.
24. Sanchez-Pernaute O, Filkova M, Gabucio A, Klein M, Maciejewska-Rodrigues H, Ospelt C, Brentano F, Michel BA, Gay RE, Herrero-Beaumont G, Gay S, Neidhart M, Juengel A: Citrullination enhances the pro-inflammatory response to fibrin in rheumatoid arthritis synovial fibroblasts. Ann Rheum Dis 2013, 72:1400-1406.
25. Sokolove J, Zhao X, Chandra PE, Robinson WH: Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcγ receptor. Arthritis Rheum 2011, 63:53-62.
26. Fearon WR: The carbamido diacetyl reaction: a test for citrulline. Biochem J 1939, 33:902-907.
27. Chikuma T, Yamada M, Tsuda A, Yamamoto M, Nakashima K, Yajima R, Kato T: A highly sensitive high-performance liquid chromatography-fluorometric method for the assay of peptidylarginine deiminase activity. Anal Biochem 2000, 285:230-234.
28. Wang Q, Priestman MA, Lawrence DS: Monitoring of protein arginine deiminase activity by using fluorescence quenching: multicolor visualization of citrullination. Angew Chem Int Ed Engl 2013, 52:2323-2325.
29. Liao YF, Hsieh HC, Liu GY, Hung HC: A continuous spectrophotometric assay method for peptidylarginine deiminase type 4 activity. Anal Biochem 2005, 347:176-181.
30. Hensen SM, Pruijn GJ: Methods for the detection of peptidylarginine deiminase (PAD) activity and protein citrullination. Mol Cell Proteomics 2014, 13:388-396.
31. Assohou-Luty C, Raijmakers R, Benckhuijsen WE, Stammen-Vogelzangs J, de Ru A, van Veelen PA, Franken KL, Drijfhout JW, Pruijn GJ: The human peptidylarginine deiminases type 2 and type 4 have distinct substrate specificities. Biochim Biophys Acta 1844, 2014:829-836.
32. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
33. Damgaard D, Palarasah Y, Skjødt K, Catrina AI, Hensen SM, Pruijn GJ, Nielsen CH: Generation of monoclonal antibodies against peptidylarginine deiminase 2 (PAD2) and development of a PAD2-specific enzyme-linked immunosorbent assay. J Immunol Methods 2014, 405:15-22.
34. Raijmakers R, Zendman AJ, Egberts WV, Vossenaar ER, Raats J, Soede-Huijbregts C, Rutjes FP, van Veelen PA, Drijfhout JW, Pruijn GJ: Methylation of arginine residues interferes with citrullination by peptidylarginine deiminases in vitro. J Mol Biol 2007, 367:1118-1129.
35. Snir O, Widhe M, von Spee C, Lindberg J, Padyukov L, Lundberg K, Engström A, Venables PJ, Lundeberg J, Holmdahl R, Klareskog L, Malmström V: Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis 2009, 68:736-743.
36. Dreyton CJ, Knuckley B, Jones JE, Lewallen DM, Thompson PR: Mechanistic studies of protein arginine deiminase 2: evidence for a substrate-assisted mechanism. Biochemistry 2014, 53:4426-4433.
37. i ) is consistently required to induce the execution phase of apoptosis. Cell Death Differ 2002, 9:561-573.
38. 2+ beneath the plasma membrane in stimulated neutrophils. Biochem Biophys Res Commun 1998, 248:679-683.